Skip to main content
SpringerLink
Log in

Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.

Methods

A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.

Results

Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30–3.78) and DFS (HR 2.63; 95 % CI 1.10–6.29) and increased RR (OR 3.29; 95 % CI 1.67–6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49–1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66–3.57) and DFS (HR 4.27; 95 % CI 1.15–15.78), increased RR (OR 3.11; 95 % CI 2.01–4.81), and decreased CRR (OR 0.42; 95 % CI 0.25–0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38–2.19) and DFS (HR 2.38; 95 % CI 1.87–3.02), increased RR (OR 5.19; 95 % CI 2.84–9.48), and decreased CRR (OR 0.62; 95 % CI 0.41–0.96).

Conclusions

This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Alegretti AP et al (2011) The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. Revista brasileira de hematologia e hemoterapia 33:202–206. doi:10.5581/1516-8484.20110054

    Article  PubMed Central  PubMed  Google Scholar 

  • Baer MR et al (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643–1648

    CAS  PubMed  Google Scholar 

  • Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  CAS  PubMed  Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458

    Article  CAS  PubMed  Google Scholar 

  • Bochtler T et al (2013) Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 31:3898–3905. doi:10.1200/jco.2013.50.7921

    Article  PubMed  Google Scholar 

  • Breccia M et al (2014) Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leuk Res 38:194–197. doi:10.1016/j.leukres.2013.11.008

    Article  CAS  PubMed  Google Scholar 

  • Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 28:43–48

    Article  CAS  PubMed  Google Scholar 

  • Chaudhri NA et al (2011) Expression of CD56 in acute myeloid leukemia (AML) is associated with poor outcome when patients treated with stem cell transplant in second remission but not in the first remission. Blood 118:2011–2012

    Google Scholar 

  • Chen G, Jia H, Bian S, Shen D, Han M, Zhang J (1997) Clinical and MIC characteristics of CD56 positive acute non-lymphoblastic leukemia. Leuk Lymphoma 36:480–482

    Google Scholar 

  • Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science (New York, NY) 236:799–806

    Article  CAS  Google Scholar 

  • Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H (2013) Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Hum Pathol 44:55–61. doi:10.1016/j.humpath.2012.04.008

    Article  CAS  PubMed  Google Scholar 

  • Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F (2002) Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 87:250–256

    PubMed  Google Scholar 

  • Djunic I et al (2012) Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. Med Oncol 29:2077–2082. doi:10.1007/s12032-011-0104-9

    Article  CAS  PubMed  Google Scholar 

  • Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729–2734

    CAS  PubMed  Google Scholar 

  • Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed) 315:629–634

    Article  CAS  Google Scholar 

  • Ferrara F, Schiffer CA (2013) Acute myeloid leukaemia in adults. Lancet 381:484–495. doi:10.1016/s0140-6736(12)61727-9

    Article  PubMed  Google Scholar 

  • Ferrara F et al (2000) CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 18:1295–1300

    CAS  PubMed  Google Scholar 

  • Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res ed) 327:557–560. doi:10.1136/bmj.327.7414.557

    Article  Google Scholar 

  • Hildreth CJ, Lynm C, Glass RM (2010) Acute myeloid leukemia. JAMA 304:2759. doi:10.1001/jama.302.22.2759

    Article  CAS  PubMed  Google Scholar 

  • Hsiao CH et al (2002) High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan. J Formos Med Assoc 101:393–398

    PubMed  Google Scholar 

  • Iriyama N et al (2013) CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res 37:1021–1026. doi:10.1016/j.leukres.2013.05.002

    Article  CAS  PubMed  Google Scholar 

  • Ito S et al (2004) Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 45:1783–1789. doi:10.1080/10428190410001683624

    Article  CAS  PubMed  Google Scholar 

  • Jiang A et al (2011a) Prognostic impact of immunophenotyping in elderly acute myeloid leukemia with normal karyotype. Lab Invest 91(Suppl. 1):303A

    Google Scholar 

  • Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H (2011b) Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leuk Res 35:492–498. doi:10.1016/j.leukres.2010.07.021

    Article  CAS  PubMed  Google Scholar 

  • Junca J et al (2014) Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Ann Hematol 93:1483–1489. doi:10.1007/s00277-014-2082-4

    Article  CAS  PubMed  Google Scholar 

  • Kohnke T et al (2014) Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia. doi:10.1038/leu.2014.186

    PubMed  Google Scholar 

  • Lanier LL, Testi R, Bindl J, Phillips JH (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169:2233–2238

    Article  CAS  PubMed  Google Scholar 

  • Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    CAS  PubMed  Google Scholar 

  • Marcucci G et al (2014) Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 32:548–556. doi:10.1200/jco.2013.50.6337

    Article  PubMed Central  PubMed  Google Scholar 

  • Mason KD, Juneja SK, Szer J (2006) The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 20:71–82. doi:10.1016/j.blre.2005.08.002

    Article  CAS  PubMed  Google Scholar 

  • Mendler JH et al (2012) RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 30:3109–3118. doi:10.1200/jco.2011.40.6652

    Article  PubMed Central  PubMed  Google Scholar 

  • Middeke JM et al (2014) Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 123:2960–2967. doi:10.1182/blood-2013-12-544957

    Article  CAS  PubMed  Google Scholar 

  • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. doi:10.1371/journal.pmed.1000097

    Article  PubMed Central  PubMed  Google Scholar 

  • Montesinos P et al (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117:1799–1805. doi:10.1182/blood-2010-04-277434

    Article  CAS  PubMed  Google Scholar 

  • Murray CK et al (1999) CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 17:293–297

    CAS  PubMed  Google Scholar 

  • Ono T et al (2014) Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci 105:97–104. doi:10.1111/cas.12319

    Article  CAS  PubMed  Google Scholar 

  • Orendi K, Emberger W, Speicher MR, Hoefler G, Sill H (2013) Molecular cytogenetics and multiplex reverse-transcriptase polymerase chain reaction for risk stratification in acute myeloid leukemia. J Clin Oncol 31:2360–2361. doi:10.1200/jco.2013.48.8189

    Article  PubMed  Google Scholar 

  • Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  CAS  PubMed  Google Scholar 

  • Pastore F et al (2014) Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol 32:1586–1594. doi:10.1200/jco.2013.52.3480

    Article  PubMed  Google Scholar 

  • Raspadori D et al (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15:1161–1164

    Article  CAS  PubMed  Google Scholar 

  • Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. doi:10.1007/s10654-010-9491-z

    Article  PubMed  Google Scholar 

  • Tan T, Wu M, Chiou L (2011) CD56 positivity is a poor prognostic factor in AML patients undergoing stem cell transplant. Bone Marrow Transplant 46:S281

    Google Scholar 

  • Thomas X, Vila L, Campos L, Sabido O, Archimbaud E (1995) Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma 19:295–300. doi:10.3109/10428199509107901

    Article  CAS  PubMed  Google Scholar 

  • Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16

    Article  PubMed Central  PubMed  Google Scholar 

  • Valgardsdottir R et al (2014) Direct involvement of CD56 in CIK-mediated lysis of CD56 hematopoietic target cells. Exp Hematol 42:1013–1021. doi:10.1016/j.exphem.2014.08.005

    Article  CAS  PubMed  Google Scholar 

  • Vardiman JW et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951. doi:10.1182/blood-2009-03-209262

    Article  CAS  PubMed  Google Scholar 

  • Wang D et al (2005) The biological and clinical significance of CD56+ antigen expression in child acute myeloid leukemia. Chin Pediatr Hematol 10:160–163

    Google Scholar 

  • Wang D et al (2006) The clinical and biological characteristics of CD56+ elderly acute myeloid leukemia. Chin J Geratol 26:1181–1183

    Google Scholar 

  • Xiong Y et al (2005) Significance of CD56 antigen expression in acute monocytic leukemia cells. J Clin Hematol 18:334–337

    Google Scholar 

  • Xu B, Xiao P, Song X, Shi P, Yi Z, Zhou S (2009) Significance of quantification of MDR1 gene and CD56 antigen expression in acute myeloid leukemia patients Chin J. Microbiol Immunol 29:1080–1083

    CAS  Google Scholar 

  • Xue A, Feng A, Zhao P, Zhang H (2013) The correlation of the expression of CD56 antigen to the relapse of acute promyelocytic leukemia. Health Res 33:345–347

    CAS  Google Scholar 

  • Yang DH et al (2007) Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 82:1–5. doi:10.1002/ajh.20739

    Article  CAS  PubMed  Google Scholar 

  • Yang LL, Gan SL, Liu YF, Zhang QT, Li T, Ma J, Sun H (2013) Clinical characteristics of CD56(+) patients with acute monocytic leukemia and their prognostic significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21:596–600. doi:10.7534/j.issn.1009-2137.2013.03.012

    CAS  PubMed  Google Scholar 

  • Zhang W et al (2001) Clinical significance and hematologic features of CD56+ acute myeloid leukemia. China Oncol 11:488–492

    Google Scholar 

  • Zhang Y et al (2002) Expression of CD56 in acute leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10:187–190

    PubMed  Google Scholar 

  • Zhang L, Ren C, Luo W, Feng C, Guo Q (2007) Expression of c-kit and CD56 in bone marrow monocyte of acute myeloid leukemia patients. Shandong Pharm Med 47:37–38

    Google Scholar 

Download references

Acknowledgments

This study was supported by National Science Foundation of China (81470324, 30971066), Postgraduate Education Reform Project of Chongqing (yjg123114), and Third Military Medical University Clinic and Science Great Fund Project (2012XLC03).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China

    Shuangnian Xu, Xi Li, Jianmin Zhang & Jieping Chen

Authors
  1. Shuangnian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianmin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jieping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jieping Chen.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Fig. 1

Sensitivity analysis of the association between CD56 expression level and a overall survival (OS), b disease free survival (DFS), c relapse rate (RR) and d complete remission rate (CRR) for AML with t(8;21) translocation by only including high quality studies. (EPS 970 kb)

Fig. 2

Sensitivity analysis of the association between CD56 expression level and a overall survival (OS), b disease free survival (DFS), c relapse rate (RR) and d complete remission rate (CRR) for AML with t(15;17) translocation by only including high quality studies. (EPS 1035 kb)

Fig. 3

Sensitivity analysis of the association between CD56 expression level and a overall survival (OS), b disease free survival (DFS), c relapse rate (RR) and d complete remission rate (CRR) for AML as a whole by only including high quality studies. (EPS 979 kb)

Supplementary material 4 (DOCX 14 kb)

Supplementary material 5 (DOC 89 kb)

Supplementary material 6 (DOC 67 kb)

Supplementary material 7 (DOC 100 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, S., Li, X., Zhang, J. et al. Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis. J Cancer Res Clin Oncol 141, 1859–1870 (2015). https://doi.org/10.1007/s00432-015-1977-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-1977-3

Keywords

Search

Navigation